Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10701
Title: Selective targeting of the tumour vasculature.
Authors: Chan, Lie S;Daruwalla, Jurstine;Christophi, Christopher
Affiliation: Department of Surgery, University of Melbourne, Austin Health, Melbourne, Victoria, Australia. l.chan11@pgrad.unimelb.edu.au
Issue Date: 1-Nov-2008
Citation: Anz Journal of Surgery; 78(11): 955-67
Abstract: Selective targeting of the tumour vasculature in the treatment of solid organ malignancies is an alternative to conventional chemotherapy treatment. As the tumour progressively increases in size, angiogenesis or the formation of new vasculature is essential to maintain the tumour's continual growth and survival. Therefore disrupting this angiogenic process or targeting the neovasculature can potentially hinder or prevent further tumour expansion. Many anti angiogenic agents have been investigated with many currently in clinical trials and exhibiting varied results. Vascular disrupting agents such as the Combretastatins and OXi 4503 have shown promising preclinical results and are currently being examined in clinical trials.
Internal ID Number: 18959693
URI: http://ahro.austin.org.au/austinjspui/handle/1/10701
DOI: 10.1111/j.1445-2197.2008.04712.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/18959693
Type: Journal Article
Subjects: Angiogenesis Inhibitors.therapeutic use
Humans
Neoplasms.blood supply.drug therapy
Neovascularization, Pathologic.prevention & control
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.